Dual doxorubicin-and verapamil-loaded liposomes with surface-conjugated transferrin successfully inhibited the doxorubicin-resistant K562 leukemia tumor cell line with about 5-fold greater potency compared to non-targeted, doxorubicin/verapamil loaded liposomes [134]. This evidence concerns the gene TF and neoplasm.